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Sputum smears for acid-fast bacilli (AFB) are the primary methods for diagnosis of tuberculosis (TB) in
many countries. The tuberculin skin test (TST) is the primary method for diagnosis of latent TB infection
(LTBI) worldwide. The poor sensitivity of the former and the poor specificity of the latter warrant the
development of new tests and strategies to enhance diagnostic capabilities. We evaluated the sensitivity of an
“in-tube” gamma interferon release assay (IGRA) using TB-specific antigens in comparison to the TST and the
sputum smear for AFB in TB cases in South Africa. The sensitivity of the IGRA for TB was considered a
surrogate of sensitivity in LTBI. Among 154 patients with a positive culture for Mycobacterium tuberculosis, the
sensitivity of the IGRA for the diagnosis of TB varied by clinical subgroup from 64% to 82%, that of the TST
varied from 85% to 94%, and that of two sputum smears for AFB varied from 35% to 53%. The sensitivity of
the IGRA in human immunodeficiency virus (HIV)-infected TB cases was 81%. HIV-infected TB patients were
significantly more likely to have indeterminate IGRA results and produced quantitatively less gamma inter-
feron in response to TB-specific antigens than HIV-negative TB patients. The overall sensitivity of the TST in
all TB cases was higher than that of the IGRA (90% versus 76%, respectively). The combined sensitivities of
the TST plus IGRA and TST plus a single sputum smear were 96% and 93%, respectively. The TST combined
with IGRA or with a single sputum smear may have a role in excluding the diagnosis of TB in some settings.
Worldwide, there were 8.8 million new cases of active tu-
berculosis (TB) and an estimated 1.7 million deaths from TB in
2003 (32). With increased numbers of TB cases, health systems
in resource-limited settings face difficulties in coping with the
large patient and specimen loads (16). Sputum smear for acid-
fast bacilli (AFB) (two or three smears) is the primary micro-
biologic method used for diagnosis of TB in resource-limited
settings. Cultures for AFB require more extensive laboratory
facilities, and their cost can be prohibitive. However, there is
concern regarding this dependence on the sputum smear for
AFB due to its limited sensitivity. Human immunodeficiency
virus (HIV) coinfection can further complicate TB diagnosis
with an atypical clinical picture of pulmonary TB and a higher
likelihood of negative sputum smears for AFB (7, 8, 12, 13, 25).
The tuberculin skin test (TST) is the standard for diagnosis of
latent tuberculosis infection (LTBI), is the only test available
for that purpose in resource-limited settings, and is sometimes
used to aid in the diagnosis of active TB; however, its specificity
is limited by cross-reactivity with nontuberculous mycobacteria
and BCG vaccine strains of Mycobacterium bovis, and its sen-
sitivity can be affected by malnutrition and immunosuppression
(17, 27).
Because of the efficacy of current therapeutic options, the
need is great for affordable and rapid diagnostic methods with
high sensitivity and specificity for TB and latent TB infections,
especially in settings of high HIV prevalence. The gamma
interferon (IFN-) release assay (IGRA) is an in vitro test
based on release of IFN- by foreign epitope-stimulated T
cells. Newly discovered antigens that are specific to the Myco-
bacterium tuberculosis complex and are not produced by My-
cobacterium bovis BCG vaccine strains offer the opportunity to
develop IGRAs with high sensitivity for TB and LTBI and high
specificity for LTBI and, potentially, for TB as well (6, 10, 18,
29). Three promising antigens for use in such assays are the
6-kDa early secreted antigenic target (ESAT-6), 10-kDa cul-
ture filtrate protein (CFP-10), and the Rv2654 antigen
(TB7.7), which are absent from BCG strains and from most
nontuberculosis mycobacteria (2). ESAT-6 and CFP-10 have
been shown to elicit strong IFN- responses from the T cells of
persons infected with M. tuberculosis but not from the T cells of
those vaccinated with BCG or at low risk of infection (3, 4, 10,
18, 23). In one recent study, conducted among hospitalized
HIV-negative patients with TB and asymptomatic subjects
considered at low risk for LTBI, the sensitivity and specificity
of a new IGRA based on two of these antigens were found to
be 89% in the former group and 98% in the latter (22), while
in another study in patients with pulmonary TB, the sensitivity
of a similar assay was 81% (19).
We evaluated the sensitivity of a new-generation IGRA in
adult patients with culture-confirmed TB in South Africa and
compared it with the sensitivity of the TST and sputum smear
for AFB. Sensitivity of the IGRA in active TB was considered
a surrogate of sensitivity of the IGRA in LTBI. The perfor-
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mance of this IGRA was also examined in a subgroup of
HIV-infected patients. Furthermore, we examined the com-
bined sensitivity of this IGRA with the TST or sputum smear
for AFB.
MATERIALS AND METHODS
Setting. The setting was a primary care facility in Gugulethu, a township of
about 70,000 people within the City of Cape Town in the Western Cape Province
of South Africa, where the 2003 tuberculosis case notification rate was 678 per
100,000. A 2003 survey for the district estimated the HIV seroprevalence to be
29%. Between 55 and 61% of TB patients in South Africa are estimated to be
HIV infected (32).
Patient recruitment and eligibility. Newly registered adult TB patients were
approached for participation in the study. Patients were eligible if they were at
least 18 years of age. Patients found subsequently not to have positive sputum
cultures were excluded from these analyses. This study complied with all federal
guidelines regarding human subject research as well as with the policies of the
individual institutions involved. All participants signed an informed consent form
approved by the institutional review boards (IRBs) of Columbia University, the
University of Cape Town, and the South African Medical Research Council.
These IRBs all approved the study protocol.
Study assessments and measurements. (i) Gamma interferon release assay.
Manufacturer’s instructions were followed precisely for the IGRA. The IGRA
(QuantiFERON-TB Gold In-Tube; Cellestis Ltd., Carnegie, Australia) was sup-
plied with three heparinized blood collection tubes precoated with the three
TB-specific antigens (ESAT-6, CFP-10, and an 18-mer peptide [AWRTAAVE
LARALVRAVA] of TB7.7), a mitogen (phytohemagglutinin), and a negative
control, respectively. Three milliliters of blood (1 ml for each tube) was collected
prior to TST administration. The tubes were mixed by shaking vigorously for 5 to
10 s to ensure that all surfaces of the tube were coated with blood and that
complete mixing of the contents had occurred. The tubes were incubated upright
overnight (16 to 24 h) at 37°C and then centrifuged at 2,200  g (relative
centrifugal force) for 10 min. Plasma (300 to 500 l) was harvested from each
tube and then refrigerated at 4°C for up to, but no more than, 4 weeks. Plasma
samples from up to 28 subjects at a time were tested by an enzyme-linked
immunosorbent assay (ELISA), whose IFN- limit of detection is 0.05 IU/ml,
using manufacturer-provided microtiter plates, IFN- standard, conjugate, wash
buffer, enzyme substrate solution, and enzyme stopping solution. Stored plasma
was vortexed to ensure that IFN- was evenly distributed throughout the sample,
and then 50-l portions of subject plasma samples were mixed with 50 l of
conjugate in the wells of the microtiter plates, which were coated with anti-
human IFN- murine monoclonal antibody. Each ELISA included a set of
recombinant IFN- standards measured in triplicate. Microtiter plates were
mixed thoroughly on a plate shaker and then incubated at room temperature for
120 min. Microtiter plate wells were then washed with 300 to 400 l of wash
buffer for nine cycles at room temperature with an ELx50 Autostrip washer
(Bio-Tek Instruments Inc., Winooski, VT). One hundred microliters of enzyme
substrate solution was added to each well, and the plates were incubated at room
temperature for a further 30 min. Following the final 30-min incubation, 50 l of
enzyme stopping solution was added to each well and mixed by gentle agitation
to terminate the ELISA. A VersaMax Tunable microplate reader (Molecular
Devices Corp., Sunnyvale, CA) was used for the reading of ELISA plates. The
optical density of each plasma sample was read using a 450-nm filter with a
620-nm reference filter within 5 min of terminating the ELISA. QuantiFERON
TB Gold Analysis software was used to calculate results from the raw optical
densities. The manufacturer’s cutoff for a positive test, indicating likely M. tu-
berculosis infection, is 0.35 IU/ml of IFN- for the TB-specific antigen-stimulated
plasma sample above the amount of IFN- in the negative control sample. The
mitogen sample is the positive control. A positive response to the TB-specific
antigens without a response to the mitogen is a valid and positive result. If there
is no detectable IFN- response to the mitogen and the TB-specific antigens, the
test is deemed “indeterminate.” The negative control adjusts for background,
heterophile antibody effects, and/or nonspecific IFN- in blood samples.
(ii) Tuberculin skin test. Two tuberculin units of PPD RT23/Tween 80 (Stat-
ens Serum Institut, Copenhagen, Denmark) in 0.1 ml were planted on the volar
surface of the left forearm via intradermal injection using a 25-gauge needle and
1-ml syringes graduated in hundredths of milliliters. Only the amount of tuber-
culin necessary for the day’s testing was taken out of cold storage at any given
time. While in the field, tuberculin was stored in insulated coolers with ice packs.
Two independent and experienced readers assessed the reaction 72 h later; each
was blinded to the other’s results and to the patient’s BCG scar status. Indura-
tions were read transversely in millimeters using calipers. Results of10 mm and
5 mm of induration were considered positive in HIV-negative or status un-
known patients and HIV-infected patients, respectively.
(iii) Smears and cultures. AFB sputum smear and culture analyses were done
at the National Health Laboratory Services in Cape Town, South Africa. Sputa
for smears were processed with NaCl-NaOH prior to auramine staining. Cultures
were done using the BACTEC 460TB system (BD Diagnostic Systems, Sparks,
MD) with 12B liquid medium as well as conventional Lowenstein-Jensen me-
dium. Midway through the study, BACTEC 460TB was replaced with BACTEC
MGIT 960. Cultures were incubated for 6 weeks. Positive cultures were con-
firmed as M. tuberculosis using the Accuprobe Mycobacterium tuberculosis com-
plex culture identification test (Gen-Probe Inc., San Diego, CA).
Information on the site of TB (pulmonary versus extrapulmonary) and cate-
gorization of cases as new or retreatment was abstracted from patient charts.
New TB cases were patients who had not been previously registered as having
TB; retreatment cases were ones previously registered. Retreatment cases in-
cluded three subcategories: (i) retreatment after cure, i.e., when previous TB
treatment was completed and a fifth-month sputum smear for AFB was negative,
(ii) retreatment after completion when previous TB treatment was completed
but no final sputum smear was performed, and (iii) retreatment after interrup-
tion of previous TB treatment for over 2 months. Number of days on anti-
tuberculosis therapy prior to phlebotomy for IGRA was recorded. HIV status
was obtained via patient self report. Presence of BCG scars was noted by physical
examination. Age and duration of symptoms prior to presentation, including
fever, night sweats, cough, hemoptysis, and loss of weight or appetite, were
recorded, as were patients’ Karnofsky performance scores (21).
(iv) Sample size and power calculations. The sample size goal was 300 patients
registered as TB cases. We assumed 50% of the patients would have a positive
sputum culture and that the IGRA would be 90% sensitive for the diagnosis of
TB disease in adults. This would provide 150 culture-positive TB patients with
whom to determine the sensitivity of the IGRA, allowing for narrow confidence
intervals of approximately 4%. We assumed the IGRA would have 95% sen-
sitivity for the diagnosis of TB in HIV-negative adults. Given knowledge of the
TB-HIV coinfection rate and the likelihood of HIV disclosure by patients, we
estimated that, of the 300 subjects, 140 would know and disclose their HIV status
and be culture positive, and of these, half would be HIV infected. We calculated
that the study would have 77% power to detect a 20% difference in sensitivity
between HIV-infected and HIV-negative groups with an n of 70 in each group.
(v) Statistical analysis. Data were entered into Access (Microsoft Corp.,
Redmond, WA) and analyzed using SPSS v12.0 (SPSS Inc., Chicago, IL). Means
were compared using the Student’s t test for two independent samples. Propor-
tions were compared using the chi-square test and the Fisher’s exact test, as
appropriate. Univariate analysis of the effect of age on outcome was analyzed
using univariate logistic regression. Multivariate analyses were done via multi-
variate logistic regression. All analyses were two sided, with P  0.05 considered
significant.
(vi) Sensitivity analyses. For all sensitivity analyses, a positive culture for M.
tuberculosis indicated true positive TB. Sensitivity was calculated by dividing the
number of individuals with a positive test (IGRA, TST, or sputum smear for
AFB) by the number of true positives. The combined sensitivity of two tests
(IGRA and TST, IGRA and a single sputum smear for AFB, or TST and a single
sputum smear for AFB) was calculated by dividing the total number of individ-
uals with a positive result to either of the two tests by the number of true
positives. Confidence intervals (CI) for sensitivity were calculated using Wilson’s
procedure without a continuity correction. The calculated sensitivity of the
IGRA for culture-confirmed active TB was used as a surrogate for its sensitivity
for LTBI, as has been done for the TST in the past (11) given the lack of a gold
standard for the diagnosis of LTBI.
RESULTS
In this study, we intended to determine with high precision
the sensitivity of a new, whole-blood, in-tube gamma inter-
feron release assay using tuberculosis-specific antigens for ac-
tive TB and, as a corollary, LTBI by analyzing the results of this
assay in patients with culture-confirmed tuberculosis. We also
wished to examine what effect, if any, HIV status may have on
the sensitivity of the IGRA. For these reasons, we enrolled TB
suspects from a primary care clinic in a high-TB-burden area












with a prevalence of HIV coinfection estimated at around
60%.
Two hundred sixty-four adult patients registered as having
TB, out of a potential 725 registered in the clinic between 15
July 2003 and 30 May 2004, were approached due to availabil-
ity of research staff only 3 days per week. Eleven patients
refused to participate. Four of the 253 patients who agreed to
participate were excluded because, on review, they were found
to be less than 18 years of age. For the remaining 249, median
age was 37 years, 38.6% were female, 87.4% had pulmonary
TB, and 62.6% were new cases (Table 1). HIV status was
known (through self report) for 70 participants, of whom 42
(60%) were HIV infected.
Of the 249 patients initially enrolled, 170 had sputum sam-
ples sent for culture. Of these, 143 had at least one positive
culture for M. tuberculosis. In addition, culture results were
available for 15 other patients with extrapulmonary TB, of
which 11 were positive for M. tuberculosis. No patients had
positive sputum smear results with negative culture results.
Thus, there were 154 patients with culture-positive TB. We
restricted all further analyses to this group of patients.
Of the 154 patients with culture-positive TB, 26 reported
being HIV infected, 15 reported being HIV negative, and 113
were status unknown. Among those who knew their HIV sta-
tus, women were more likely than men to be HIV infected
(odds ratio [OR], 3.43; 95% CI, 1.25 to 9.40; P  0.027, Fish-
er’s exact test). The median Karnofsky scores were 80 in the
HIV-infected group and 90 in the other two groups.
One hundred thirty-eight patients with culture-positive pul-
monary TB had results from at least one sputum smear for
AFB, and 100 patients had results from two sputum smears
available. Forty-nine of 138 cases of pulmonary TB had a
positive first sputum smear for AFB, resulting in a single spu-
tum smear sensitivity of 36%, while two sputum smears in-
creased the sensitivity to 52% (Table 2). The sensitivity of two
smears was 35% in HIV-infected patients.
Of the 154 patients with positive cultures for M. tuberculosis,
23 had indeterminate IGRA results. The remaining 131 had
interpretable IGRA results, and of these, 100 had a positive
IGRA result for an overall sensitivity of 76% (95% CI, 68% to
83%), which increased to 82% (95% CI, 71% to 89%) when
analysis was restricted to new pulmonary TB cases. There was
a median of 3 days (interquartile range, 0 days and 6 days)
between start of TB treatment and phlebotomy for the IGRA.
In a subgroup analysis of patients with known HIV status, the
sensitivity of the IGRA was higher in HIV-infected patients
than in HIV-negative patients (81% versus 73%) (Table 2).
However, of the 41 patients with known HIV status (26 HIV
infected and 15 HIV negative), five had indeterminate results,
all of whom were HIV infected (19% versus 0%, respectively;
P  0.139, Fisher’s exact test). If these five indeterminate
results were considered negative, then the sensitivity of the
IGRA in HIV-infected individuals with culture-proven TB
would be 65% (95% CI, 46% to 81%). IFN- levels were
significantly lower in HIV-infected patients than in HIV-neg-
ative patients with culture-positive TB (P  0.033; Table 3).
There were 18 patients with indeterminate IGRA results for
whom HIV status was unknown.
On univariate analysis, sex, age, days from start of TB ther-
apy to phlebotomy, Karnofsky score, HIV status, and site of
TB were not associated with IGRA result. However, patients
with at least one BCG scar on physical examination were more
likely to have a positive IGRA result (OR, 2.1; 95% CI, 1.1 to
4.2; P  0.032, Fisher’s exact test). In addition, patients with
new cases of TB were more likely to have a positive IGRA than
those retreated for TB (OR, 2.3; 95% CI, 1.3 to 4.2; P 0.008,
Fisher’s exact test). In multivariate analysis adjusting for sex,
age, HIV status, and type of TB, the BCG scar association was
no longer statistically significant (OR, 2.0; 95% CI, 0.99 to 4.0;
P  0.052), while patients with new cases of TB remained










Total no. of patients 249 62 154
Female (n [%]) 96 (38.6) 23 (37) 58 (37.7)
Mean age (yr)
Male 38a 36.5 38
Female 34.9 33 36.5
TB typeb (n 	%
)
Pulmonary 215 (87.4) 45 (72.6) 143 (92.9)
Pleural 19 (7.7) 8 (12.9) 7 (4.5)
Other 8 (3.3) 5 (8.1) 4 (2.6)
Lymph 4 (1.6) 4 (6.4) 0 (0)
TB registrationc (n 	%
)
New 154 (62.6) 46 (74.2) 97 (63.4)
Retreatment
After completion 61 (24.8) 13 (21) 38 (24.8)
After cure 20 (8.1) 0 13 (8.5)
After interruption 11 (4.5) 3 (4.8) 5 (3.3)
HIV status (n 	%
)
Status unknown 179 (71.9) 45 (72.6) 112 (72.7)
Infected 42 (16.9) 11 (17.7) 26 (16.9)
Negative 28 (11.2) 6 (9.7) 16 (10.4)
BCG scarsd (n 	%
)
None 58 (24.5) 14 (23.3) 39 (25.7)
Doubtful 22 (9.3) 5 (8.3) 13 (8.6)
1 107 (45.1) 31 (51.7) 63 (41.4)
2 36 (15.2) 7 (11.7) 25 (16.4)
3 14 (5.9) 3 (5) 12 (7.9)
Symptoms (median wk 	IQRe
)
Cough 4 (2–4) 3 (1–4) 4 (2–6)
Hemoptysis 0 0 0
Fever 0 (0–2) 0 (0–1) 0 (0–3)
Night sweats 3 (2–4) 3 (1–4) 3 (2–4)
Loss of appetite 3 (1–4) 1 (0–3) 3 (0–4)
Loss of weight 2 (0–4) 2 (1–3) 3 (2–4)
Median Karnofsky score
(range)
90 (70–90) 90 (90–90) 90 (80–90)
a Difference in mean ages between male and female significant; Student’s t
test, P  0.019.
b TB type was unavailable for 3 of the initial 249 patients.
c TB registration was unavailable for 3 of the initial 249 patients.
d BCG scar status was unavailable for 12 of the initial 249 patients.
e IQR, interquartile range.












significantly more likely to have a positive IGRA than retreat-
ment patients (OR, 2.2; 95% CI, 1.1 to 4.5; P  0.028).
One hundred forty-six (95%) of the 154 patients with cul-
ture-positive TB had TST results. Of these, only two patients,
one who was HIV negative and another with unknown HIV
status, had indurations of 0 mm but 10 mm. For this rea-
son, all further analyses were done with induration of 10 mm
considered positive irrespective of HIV status. Thirty-three
patients had only one TST reading. Of the 121 with two TST
readings, overall agreement between the two readers was 99%,
with a kappa statistic of 0.961. Because of this high level of
agreement, all further analysis was done using the result from
the first TST only. One hundred thirty-one of the 146 patients
had a positive TST for an overall sensitivity of 90% (95% CI,
84% to 94%) (Table 2). On univariate analysis, sex, age, days
from start of TB therapy, Karnofsky score, HIV status, site of
TB, type (new versus retreatment) of TB, and BCG scar status
were not associated with TST result. In multivariate analysis,
no other associations were found.
There were 126 patients with culture-positive TB who had
both a valid IGRA result and a TST result. The absolute
agreement between the tests in these 126 patients was 74.6%,
with a kappa statistic of 0.118. The combined sensitivity of the
IGRA and TST in culture-confirmed TB was 96% (95% CI,
91% to 98%) (Table 4). In the subset of patients with pulmo-
nary TB, the combined sensitivity remained at 96% (110/115;
95% CI, 90% to 98%). The sensitivities of the IGRA and the
TST for diagnosis of pulmonary TB exceeded that of one or
two sputum smears for AFB (Table 5). A single sputum smear
combined with the IGRA resulted in a sensitivity of 86% (95%
CI, 79% to 91%) for culture-proven pulmonary TB. A single
sputum smear combined with the TST resulted in a sensitivity
of 93% (95% CI, 87% to 96%) for culture-positive pulmonary
TB (Table 6).
DISCUSSION
The diagnosis of TB in many resource-limited settings is
restricted by the low sensitivity of the sputum smear for AFB,
the most widely available test for the diagnosis of TB. The
diagnosis of LTBI worldwide is limited by the poor specificity
of the TST. The development of new TB diagnostic methods
which are feasible and affordable to use in areas with limited
resources and high HIV seroprevelance has become a world-
wide priority. Studies of in vitro tests which measure the re-
lease by immune cells of gamma interferon when stimulated
with TB-specific antigens have focused on their usefulness for
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All typesc 100/131 76 (68–83) 131/146 90 (84–94) NAd NA NA NA
New 67/82 82 (72–89) 84/92 91 (84–96) NA NA NA NA
Retreatment 33/49 67 (53–79) 47/54 87 (76–94) NA NA NA NA
HIV negative 11/15 73 (48–89) 15/16 94 (72–99) NA NA NA NA
HIV infected 17/21 81 (60–92) 22/26 85 (66–94) NA NA NA NA
All pulmonary TB 90/120 75 (67–82) 122/135 90 (84–94) 49/138 36 (28–44) 52/100 52 (42–62)
New 62/76 82 (71–89) 79/86 92 (84–96) 28/88 32 (22–43) 47/88 53 (42–64)
Retreatment 28/44 64 (49–76) 43/49 88 (76–945) 21/50 42 (28–57) 25/50 50 (36–64)
HIV negative 10/13 77 (50–92) 13/14 93 (69–99) 2/13 15 (2–45) 6/13 46 (19–75)
HIV infected 15/19 79 (57–91) 21/24 88 (69–96) 3/24 13 (3–32) 7/20 35 (15–59)
a True positive was defined as culture positive for Mycobacterium tuberculosis.
b The Wilson procedure was used to determine confidence intervals (without continuity correction).
c Includes pulmonary and extrapulmonary TB cases.
d NA, not applicable.
e Values are percentages.
TABLE 3. Comparison of mean IFN- responses to antigens in 26
HIV-infected versus 15 HIV-negative patients
with culture-positive TB
Antigens HIV status Mean IFN-(IU/ml)
SD
(IU/ml)
Negative control Positive 0.25 0.27
Negative 0.72 1.38
ESAT-6, CFP-10, Positive 1.29 1.37
and TB7.7 Negative 8.19a 11.24
Mitogen Positive 4.23 7.49
Negative 5.91 6.08




a P  0.033; Student’s t test, equal variances not assumed.
TABLE 4. Agreement between and combined sensitivity of the
IGRA and the TST in culture-proven cases of active TBa
TST
result
No. of patients tested by IGRA
Total
Negative Positive
Negative 5 7 12
Positive 25 89 114
Total 30 96 126
a Absolute agreement, 74.6%; kappa, 0.118; combined sensitivity, 96%.












the diagnosis of LTBI. We assessed the sensitivity of a new
whole-blood “in-tube” IFN- release assay to active TB, a
measure which has been used as a surrogate for sensitivity to
LTBI, and also examined possible strategies to maximize the
sensitivity of this assay in combination with the TST and spu-
tum smear for AFB in the diagnosis of TB.
The overall sensitivity of the IGRA in our study was 75% in
all the patients with pulmonary TB, which increased to 82% in
new cases of pulmonary TB. This finding is in contrast to the
sensitivity of the sputum smear for AFB, the standard meth-
odology for diagnosis of TB in this setting, which was 52% and
53% for two smears in these same two groups of TB patients,
respectively. The sensitivity of the TST, at 90% in all pulmo-
nary TB cases and 92% in new pulmonary TB cases, was the
highest of all three modalities. The IGRA and TST both had
higher sensitivities than the sputum smear in a population in
whom HIV status was largely unknown but in a setting where
the rate of TB cases with HIV coinfection has been estimated
at around 60% (32).
Prior studies have reported the sensitivity of sputum smear
for AFB to vary widely between 50 and 80% (5, 15, 20, 33). The
low sensitivity of the sputum smear for the diagnosis of pul-
monary TB noted in our study is consistent with these reports
but may also reflect the effect of high TB-HIV coinfection rates
on clinical features of pulmonary TB and associated sputum
smear positivity.
The sensitivity of the IGRA was slightly, although not sig-
nificantly, higher in self-reported HIV-infected individuals
than in those self reported as HIV negative. The subgroup of
participants with known HIV status was small, leading to very
wide confidence intervals for these two estimates. Further
studies are needed to examine this finding. It is important to
note that the mean levels of IFN- produced in response to
exposure to the TB-specific antigens were significantly lower in
HIV-infected patients than in HIV-negative patients. In addi-
tion, all indeterminate results occurred among HIV-infected
patients. This was due to lack of response to both the TB-
specific antigens as well as to the mitogen, most likely reflect-
ing the effect of HIV infection on the number and function of
T cells. Thus, the sensitivity (and potentially the usefulness) of
this test for the diagnosis of LTBI and as an aid in the diagnosis
of TB in HIV-infected patients may be reduced. More studies
in HIV-infected individuals, stratified by level of immunosup-
pression, are needed.
The IGRA was less sensitive (67%) in the small subgroup of
patients who were being retreated for TB for unclear reasons.
As the percentage of patients with concomitant HIV infection
is likely to be higher among patients with recurrent TB disease
than new cases, the observed reduction in the sensitivity among
retreatment cases may be due to HIV infection and low CD4
counts. It is important to note that retreatment cases consti-
tuted nearly one third of the patients in this study and at least
10% of TB patients in South Africa (31). Thus, new diagnostic
tests for TB would ideally have high sensitivity in both new TB
cases and in retreatment of TB. The TST displayed remarkably
stable sensitivity, ranging from 85% to 94%, regardless of
clinical subgroup.
Evidence of BCG scar among study participants was surpris-
ingly associated with a nonstatistical trend for the IGRA to be
positive. Further studies are needed to confirm this finding.
This is unexpected, given that the TB-specific antigens used in
the IGRA are on genes not conserved in the genome of M.
bovis strains used in BCG vaccines. While 66% of patients had
evidence of BCG scars, it is recognized that not all vaccinated
individuals develop a scar (14, 24), potentially leading to mis-
classification. Therefore, BCG scar status may not accurately
reflect prior BCG vaccination.
We found overall agreement between the IGRA and TST to
be moderate, at 74.6%, with a weak kappa statistic of 0.118.
However, these two tests may not be measuring the same
phenomena. It is thought that new-generation IFN- assays,
with their short incubation periods, measure mostly effector
T-cell responses to antigens, as opposed to the TST, which
measures both effector and memory T-cell responses (9). Thus,
inconsistent or low levels of agreement between the two tests
may not be surprising. This possible difference in what immune
responses the two tests measure may also warrant caution
when interpreting the meaning of a positive IGRA in patients
being tested for LTBI, as the exact predictive value of a pos-
itive IGRA (i.e., its correlation with future risk of development
of TB) awaits more extensive study in prospective cohorts (28).
TABLE 5. Head-to-head comparison of sensitivities of IGRA, TST,









One sputum smear for AFB 37/112 33 (25–42)
IGRA 84/112 75 (66–82)
TST 102/112 91 (84–95)
Two sputum smears for AFB 42/83 51 (40–61)
IGRA 66/83 80 (70–87)
TST 75/83 90 (82–95)
a A sputum culture that was positive for Mycobacterium tuberculosis was con-
sidered a true positive result.
b Values are percentages.
c The Wilson procedure for confidence intervals without continuity correction
was used.
TABLE 6. Combined sensitivity of IGRA and TST with a single
sputum smear for AFB in culture-positive pulmonary TB
Test and result
No. of patients with smear
result that was: Total
Negative Positive
IGRAa
Negative 16 13 29
Positive 60 28 88
Total 76 41 117
TSTb
Negative 9 4 13
Positive 78 39 117
Total 87 43 130
a Combined sensitivity of the IGRA and smear, 101/117 (86%).
b Combined sensitivity of the TST and smear, 121/130 (93%).












Strategies for screening individuals suspected of having pul-
monary TB using both the IGRA and TST or IGRA and single
sputum smear for AFB could have attractive negative predic-
tive values, given the high sensitivity obtained by using combi-
nations of these tests. Further studies of such strategies in
regions of varying TB prevalence are warranted. In this study,
of the 30 TB suspects with results available for both the IGRA
and TST whose cultures eventually came back negative, 17 had
a positive IGRA and 25 had a positive TST. Although these 30
TB suspects may not be representative of all TB suspects, this
suggests that in high-TB-burden areas, strategies for screening
TB suspects using combinations of these tests may not be very
useful, given the inability of both the TST and IGRA to dis-
tinguish between active TB and LTBI. However, this does not
preclude their utility in low- or medium-TB-burden areas,
where the positive predictive value of a screening strategy for
active TB using combined testing may be higher. Whether any
of these strategies for screening patients with suspected TB,
irrespective of level of TB burden, could be useful in reducing
overall programmatic costs through the exclusion of TB and
the reduction in the need for multiple sputum smears, cultures,
and other diagnostic modalities will require cost effectiveness
analyses of these new diagnostic assays (30), as has been done
for other new rapid TB-diagnostic technologies (1).
The main advantage of IGRAs which use TB-specific anti-
gens are their increased specificity for the diagnosis of LTBI
compared to the TST. A limitation of our study was the in-
ability, by design, to assess the specificity of the IGRA we
studied. The IGRA’s requirement of a single visit to obtain a
test result and ability to analyze samples from multiple indi-
viduals at once are attractive characteristics for use in LTBI
prevalence surveys and for diagnosis of LTBI in clinical set-
tings where treatment of LTBI is offered. On the other hand,
the need for venipuncture could limit its usefulness in children
(26). Its current cost and the need for trained laboratory staff
and a laboratory equipped to perform ELISA may limit these
advantages in resource-limited settings.
Conclusions. This study examined the sensitivity of a new
generation of IGRA using “in-tube” TB-specific antigens. The
sensitivity of the IGRA in individuals with active TB was used
as a surrogate for its sensitivity in LTBI. The IGRA demon-
strated high overall sensitivity, although not as high as that of
the TST, with highest sensitivity in new pulmonary TB patients.
HIV-infected TB patients were more likely to have indetermi-
nate IGRA results than HIV-negative patients. The sensitivity
of the TST combined with the IGRA or sputum smear for AFB
was high in pulmonary TB suspects, which may make it suit-
able, in some settings, to use such a combined testing strategy
to exclude a diagnosis of pulmonary TB, given its potentially
high negative predictive value. Newer diagnostics, such as this
IGRA, have created exciting possibilities for improvements in
the diagnosis of LTBI and for use as adjuncts in the diagnosis
of TB disease.
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